News

31. BioMarin Announces IND For BMN-111 For Achondroplasia Is Active 1/4/2012
    BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Investigational New Drug (IND) application for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia is active. The company expects to initiate the Phase 1 trial in the first quarter of 2012.
32. Clinical Hold Removed For Helix Biopharma Corp.'s Topical Interferon Alpha-2B Phase II/III Efficacy Trial IND Application 11/14/2011
    Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that the “clinical hold” on its investigational new drug (“IND”) application for its Topical Interferon Alpha-2b, Phase II/III, low-grade cervical lesion efficacy trial has been removed by the United States Food and Drug Administration (“FDA”).